# ARTMS Products

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/artms-products

- Industry: Medical Devices & Equipment
- Headquarters: Burnaby, Canada
- Website: www.artms.ca
- Total disclosed funding: $22M
- Latest round: Series A (May 20, 2020)
- Investors on record: 3

## About

Founded in 2013 and based in Burnaby, British Columbia, Canada, Artms, Inc. develops machines to facilitate cyclotron production using diagnostic imaging isotopes. In March 2024, Telix Pharmaceuticals Limited a portfolio company of CVC Capital Partners, Viburnum Funds, and Acorn Capital agreed to acquire Artms, Inc. for USD 42.5 million.

 The company offers solutions for the development of diagnostic imaging isotopes. The firm solution range includes gallium-68 (68Ga), technetium-99m (99mTc), zirconium-89 (89Zr) and copper-64 (64Cu). To simultaneously create certain GMP medicinal isotopes, the company also collaborates with radiopharmaceutical and biotechnology firms. 

 The March 2024 acquisition may help Artms, Inc. develop its isotopes diagnostic imaging device and increase its production.

## Funding rounds

- Series A, May 20, 2020, $19M — Deerfield Management, GF Securities, Quark Venture
- Seed, Dec 18, 2017, $3M — GF Securities, Quark Venture

## Investors

- GF Securities — Seed, Series A
- Quark Venture (https://capitalatlas.ai/funds/quark-venture) — Seed, Series A
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A